Citigroup Lowers IQVIA (NYSE:IQV) Price Target to $200.00

IQVIA (NYSE:IQV) had its target price decreased by stock analysts at Citigroup from $230.00 to $200.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage currently has a “neutral” rating on the medical research company’s stock. Citigroup’s price objective suggests a potential upside of 6.87% from the stock’s previous close.

Several other brokerages have also issued reports on IQV. Wall Street Zen raised IQVIA from a “hold” rating to a “buy” rating in a research note on Sunday, January 25th. Evercore ISI reissued an “outperform” rating and set a $225.00 price objective on shares of IQVIA in a report on Thursday. TD Cowen raised their target price on shares of IQVIA from $215.00 to $245.00 and gave the company a “hold” rating in a research note on Thursday, January 22nd. Weiss Ratings reissued a “hold (c)” rating on shares of IQVIA in a research note on Thursday, January 22nd. Finally, Truist Financial raised their price objective on shares of IQVIA from $265.00 to $290.00 and gave the company a “buy” rating in a research note on Thursday, January 8th. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $243.63.

IQVIA Price Performance

Shares of NYSE:IQV traded up $6.19 during midday trading on Friday, reaching $187.15. The company’s stock had a trading volume of 2,332,017 shares, compared to its average volume of 1,633,401. The business’s fifty day simple moving average is $228.83 and its 200-day simple moving average is $209.42. The company has a market capitalization of $31.87 billion, a P/E ratio of 25.64, a P/E/G ratio of 2.06 and a beta of 1.37. The company has a debt-to-equity ratio of 2.03, a current ratio of 0.70 and a quick ratio of 0.70. IQVIA has a fifty-two week low of $134.65 and a fifty-two week high of $247.04.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Thursday, February 5th. The medical research company reported $3.42 EPS for the quarter, topping analysts’ consensus estimates of $3.40 by $0.02. IQVIA had a net margin of 8.07% and a return on equity of 30.70%. The firm had revenue of $4.36 billion for the quarter, compared to analyst estimates of $4.24 billion. During the same quarter in the prior year, the firm earned $3.12 EPS. The company’s revenue was up 10.3% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. As a group, equities research analysts expect that IQVIA will post 10.84 EPS for the current fiscal year.

Hedge Funds Weigh In On IQVIA

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Brighton Jones LLC grew its stake in shares of IQVIA by 244.4% in the 4th quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock valued at $703,000 after purchasing an additional 2,537 shares during the last quarter. Empowered Funds LLC increased its stake in IQVIA by 102.1% in the 1st quarter. Empowered Funds LLC now owns 9,728 shares of the medical research company’s stock valued at $1,715,000 after purchasing an additional 4,915 shares in the last quarter. Sivia Capital Partners LLC acquired a new position in IQVIA during the second quarter worth $514,000. DAVENPORT & Co LLC grew its holdings in IQVIA by 6.7% in the second quarter. DAVENPORT & Co LLC now owns 2,449 shares of the medical research company’s stock valued at $386,000 after purchasing an additional 153 shares during the last quarter. Finally, KLP Kapitalforvaltning AS increased its position in shares of IQVIA by 1.7% in the second quarter. KLP Kapitalforvaltning AS now owns 64,675 shares of the medical research company’s stock valued at $10,192,000 after buying an additional 1,100 shares in the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Key Stories Impacting IQVIA

Here are the key news stories impacting IQVIA this week:

• Positive Sentiment: Q4 results beat expectations — EPS $3.42 vs. ~$3.40 consensus and revenue $4.36B vs. ~$4.24B; revenue grew double digits year‑over‑year, supporting demand recovery from pharma clients. IQVIA Q4 Earnings & Revenues Beat Estimates
• Positive Sentiment: Company issued FY‑2026 guidance (EPS 12.55–12.85; revenue $17.2B–$17.4B) that is near or modestly above consensus revenue, giving a baseline for 2026 recovery expectations. IQVIA FY2026 Guidance (press materials)
• Neutral Sentiment: Analyst research/forecast pages provide varying takes on valuation and forward estimates — useful for modeling revisions but not a single consensus driver. IQVIA Stock Forecasts (Yahoo)
• Negative Sentiment: Market reaction and some coverage flagged the FY outlook as disappointing after accounting for higher interest expense — Reuters and others note annual profit forecasts were lowered, which dented sentiment and prompted price weakness in some sessions. IQVIA forecasts weak annual profit on higher interest expenses
• Negative Sentiment: Several outlets reported that the 2026 outlook missed portions of Wall Street expectations for adjusted earnings, triggering intraday selling and negative headlines. IQVIA Stock Drops as 2026 Outlook Misses
• Negative Sentiment: Analysts questioned the near‑term payoff from IQVIA’s AI strategy and at least one firm (BTIG) cut its rating to neutral, adding to downside pressure. IQVIA backs AI strategy as analysts question impact BTIG cuts IQVIA rating to neutral

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.